Research programme: anti-inflammatory therapeutics - Pulmagen Therapeutics

Drug Profile

Research programme: anti-inflammatory therapeutics - Pulmagen Therapeutics

Alternative Names: ADC 3277; CHI 25243

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pulmagen Therapeutics
  • Class Anti-inflammatories
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute asthma; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 02 Feb 2017 Preclinical development is ongoing in United Kingdom (Pulmagen Therapeutics pipeline, February 2017)
  • 03 Sep 2016 Pharmacodynamics data from preclinical studies in Chronic obstructive pulmonary disease presented at the 26th Annual Congress of the European Respiratory Society
  • 01 Jul 2011 Pulmagen Therapeutics signs a service agreement with Argenta
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top